Evaluation of Colorectal Cancer Screening Strategies in China
NCT ID: NCT05440552
Last Updated: 2022-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20000 participants
INTERVENTIONAL
2022-07-31
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Different Colorectal Cancer Screening Strategies
NCT05440565
A Comparison of Different Fecal Occult Blood Test for Colorectal Cancer Screening
NCT04454099
Multiple Screening Methods for the Detection of Chinese Colorectal Advanced Adenomatous Polyps and Cancer
NCT03411707
Colorectal Cancer Screening in Chinese Rural Communities
NCT07180303
A Multicenter Clinical Trial of Stool-based DNA Testing for Early Detection of Colon Cancer in China
NCT04722055
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SCREENING
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Risk score1
Qualitative Fecal immunochemical test + APCS score
Risk stratification using Qualitative Fecal immunochemical test and APCS score
Risk score2
Quantitative Fecal immunochemical test
Use Quantitative Fecal immunochemical only for risk stratification
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Qualitative Fecal immunochemical test + APCS score
Risk stratification using Qualitative Fecal immunochemical test and APCS score
Quantitative Fecal immunochemical test
Use Quantitative Fecal immunochemical only for risk stratification
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent is available
Exclusion Criteria
* Previous colorectal resection
* Previous received cancer-related treatment (except non-melanoma skin cancer)
* Colonoscopy, sigmoidoscopy, CT colonoscopy, and barium enema were performed within 5 years
* Fecal occult blood or fecal DNA was performed within one year
* Symptoms of lower digestive tract diseases requiring colonoscopy include: (1) rectal bleeding occurred more than once in the past 6 months, (2) recorded iron deficiency anemia, and (3) recorded significant weight loss within 6 months (\> 10% of baseline weight - Suffering from other diseases that affect the benefit of screening or intolerance to colonoscopy (for example, severe pulmonary disease, end-stage renal disease, end-stage liver disease, severe heart failure or recently diagnosed cancer, except non-melanoma skin cancer)
50 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yanqing Li
Vice President of Qilu Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022SDU-QILU-107
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.